Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Dividend Derby: Pfizer Vs. Merck
Motley Fool
Saturday, February 22, 2014 - 11:26am
tags:
Pfizer, Merck
Pozen's Wagon is Tied to Horizon and Sanofi
Motley Fool
Saturday, February 22, 2014 - 11:25am
tags:
Pozen, Sanofi, Horizon Therapeutics
Does Bristol-Myers Squibb Co. Have Any Fuel Left in its Tank?
Motley Fool
Saturday, February 22, 2014 - 11:23am
tags:
Bristol-Myers Squibb
Pfizer-MIT Partnership to Streamline Production of Biologic Drugs
Wall St Cheat Sheet
Saturday, February 22, 2014 - 11:23am
tags:
Pfizer
FDA looks to reboot nonprescription drug system
Yahoo/AP
Saturday, February 22, 2014 - 11:22am
tags:
FDA, OTC
OncoMed Commences Study on OMP-54F28
Yahoo/Zacks
Saturday, February 22, 2014 - 10:54am
tags:
OncoMed, OMP-54F28, ovarian cancer
Arena's Belviq Sales Continue Up As Others Decline
Seeking Alpha
Saturday, February 22, 2014 - 10:51am
tags:
Arena Pharmaceuticals, Belviq, weight loss, obesity
Incyte May Be Undervalued Even After Rise, New CEO Says
Bloomberg
Saturday, February 22, 2014 - 10:49am
tags:
Incyte
Vertex announces FDA approval of KALYDECO
Yahoo/The Fly on the Wall
Saturday, February 22, 2014 - 10:45am
tags:
Vertex Pharmaceuticals, Kalydeco, cystic fibrosis
Geron: A Biotech Stock With Potential For Long-Term Gains
Seeking Alpha
Saturday, February 22, 2014 - 10:43am
tags:
Geron
Gilead: AbbVie No Match For Sovaldi
Barron's
Saturday, February 22, 2014 - 10:41am
tags:
Gilead Sciences, AbbVie, Sovaldi, hepatitis, hepatitis C
2 FDA Decisions You Need to Watch Next Week
Motley Fool
Friday, February 21, 2014 - 5:12pm
tags:
FDA, metreleptin, Bristol-Myers Squibb, lipodystrophy, AstraZeneca, hypogonadism, Endo Health Solutions, Aveed
Endo to Pay $193 Million in Lidoderm Marketing Probe
Bloomberg
Friday, February 21, 2014 - 5:01pm
tags:
Endo Health Solutions, whistleblower lawsuits, lidoderm
Isis shares jump on promising spinal disorder treatment data
Yahoo/Reuters
Friday, February 21, 2014 - 5:01pm
tags:
Isis Pharmaceuticals, ISIS-SMN, antisense, Biogen Idec
Pfizer-MIT Partnership to Streamline Production of Biologic Drugs
Wall St Cheat Sheet
Friday, February 21, 2014 - 4:59pm
tags:
Pfizer, MIT, R&D, drug discovery
ANI Pharmaceuticals: Nothin' Generic About It
Seeking Alpha
Friday, February 21, 2014 - 11:31am
tags:
ANI Pharmaceuticals, generics, Teva Pharmaceuticals
Top 10 generics makers by 2012 revenue
Fierce Pharma
Friday, February 21, 2014 - 11:29am
tags:
generics
Cannabis Science Inc negotiates $1 mln financing for progression of products and start of observational trials
Reuters
Friday, February 21, 2014 - 11:24am
tags:
Cannabis Science
Previous Data Signals Positive Phase IIb Results Likely To Come For Synergy Pharmaceuticals
Seeking Alpha
Friday, February 21, 2014 - 11:19am
tags:
Synergy Pharmaceuticals, IBS-C, Ironwood Pharmaceuticals, Linzess, Sucampo, plecanatide
Bristol-Myers reports positive results from Phase 3 ARISTOTLE trial
Yahoo/Fly on the Wall
Friday, February 21, 2014 - 11:16am
tags:
Bristol-Myers Squibb, Pfizer, Eliquis, bloodthinners

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.